Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 12,500 shares of the company's stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $22.52, for a total transaction of $281,500.00. Following the transaction, the chief executive officer directly owned 940,392 shares of the company's stock, valued at approximately $21,177,627.84. This represents a 1.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Samuel Kintz also recently made the following trade(s):

• On Tuesday, June 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.18, for a total transaction of $277,250.00.
• On Tuesday, June 3rd, Samuel Kintz sold 7,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.05, for a total transaction of $150,375.00.
• On Monday, May 19th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.49, for a total value of $82,450.00.
• On Thursday, May 1st, Samuel Kintz sold 5,330 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.08, for a total value of $107,026.40.

Enliven Therapeutics Price Performance

NASDAQ ELVN traded up $0.70 on Wednesday, reaching $22.26. The company had a trading volume of 48,821 shares, compared to its average volume of 306,902. The firm has a market capitalization of $1.09 billion, a PE ratio of -11.55 and a beta of 0.83. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $30.03. The firm has a 50-day moving average of $20.16 and a 200-day moving average of $20.23.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). As a group, sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analyst Ratings Changes

ELVN has been the subject of a number of research reports. The Goldman Sachs Group initiated coverage on Enliven Therapeutics in a report on Monday, June 16th. They set a "buy" rating and a $37.00 target price for the company. Jones Trading decreased their target price on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a report on Friday, May 16th. Robert W. Baird boosted their target price on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, June 16th. Finally, HC Wainwright boosted their target price on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a report on Wednesday, July 2nd. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Enliven Therapeutics presently has an average rating of "Buy" and an average price target of $41.20.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in ELVN. Ameriprise Financial Inc. acquired a new stake in Enliven Therapeutics in the fourth quarter worth $789,000. Millennium Management LLC boosted its stake in Enliven Therapeutics by 108.6% during the fourth quarter. Millennium Management LLC now owns 50,804 shares of the company's stock valued at $1,143,000 after buying an additional 26,449 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Enliven Therapeutics by 67.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company's stock valued at $984,000 after buying an additional 17,546 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Enliven Therapeutics by 4.9% during the first quarter. Rhumbline Advisers now owns 52,502 shares of the company's stock valued at $1,033,000 after purchasing an additional 2,466 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Enliven Therapeutics by 2.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company's stock worth $5,892,000 after acquiring an additional 6,611 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.